>On the surface it just seems that if a MOA is poorly understood, then it very well may have to do with complex interactions that a cell culture/in vitro assay just cannot predict<
The benefit of ribavirin may not be all that complicated. Riba's main contribution is probably that it works well against mutant strains while NM283 works mostly against wild-type HCV.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”